Feline Toxoplasmosis: Etiology, Clinical Signs, Diagnosis, Treatment, and Zoonotic Considerations

Etiology and Life Cycle

Feline toxoplasmosis is caused by the obligate intracellular apicomplexan parasite Toxoplasma gondii. Felids, including domestic cats, serve as the only definitive hosts for this protozoan, meaning that sexual replication occurs exclusively within the feline intestinal epithelium [1, 2]. The parasite exists in three infectious stages: tachyzoites (rapidly dividing forms), bradyzoites (slowly dividing forms contained within tissue cysts), and sporozoites (within sporulated oocysts) [1, 3]. Cats become infected through predation or ingestion of tissue cysts containing bradyzoites from intermediate hosts, such as rodents or birds [4, 3]. After ingestion, the bradyzoites excyst in the small intestine, invade enterocytes, and undergo a series of asexual developmental stages including schizogony, during which merozoites are produced [2]. Schizogony is followed by gametogony and oocyst formation, culminating in the shedding of unsporulated oocysts in feces [1, 2]. The prepatent period after ingestion of tissue cysts is typically 3 to 10 days, whereas after ingestion of oocysts, the prepatent period is longer, ranging from 18 days or more [5, 33]. Oocysts sporulate in the environment within 1 to 5 days under appropriate conditions of temperature and humidity, becoming infectious to a wide range of warm-blooded animals [1, 3]. The entero-epithelial cycle is largely responsible for environmental contamination, as a single infected cat can shed millions of oocysts [1, 2]. After the initial intestinal infection, the parasite disseminates via the bloodstream and lymphatics as tachyzoites, invading nucleated cells throughout the body [3]. Immune pressure induces conversion to bradyzoites, which form tissue cysts primarily in skeletal muscle, myocardium, and neural tissues including the brain [3, 5]. These cysts persist for the life of the host, providing a reservoir for potential recrudescence in immunocompromised states [6, 5]. The life cycle in cats is unique because the entero-epithelial stage is limited to felids, and the expression of micronemal proteins such as MIC17A is markedly upregulated during the merozoite stage, providing a basis for stage-specific diagnostic approaches [2, 7].

Transmission

Transmission of T. gondii to cats occurs predominantly through the ingestion of tissue cysts in raw or undercooked meat from intermediate hosts [3, 8]. Hunting behavior is a significant risk factor, as cats that prey on birds and rodents have higher seroprevalence rates [4, 8]. A study of 1554 cats in Greece reported that rural cats and those with outdoor access had significantly higher seropositivity, and hunting in urban areas remained a significant risk factor after multivariate adjustment [4]. Ingestion of sporulated oocysts from contaminated soil, water, or prey is another route, though the prepatent period is longer [5, 27]. Vertical transmission via transplacental tachyzoite migration can occur during primary infection in pregnant queens, leading to fetal resorption, abortion, or congenital disease in kittens [3, 26]. Lactational transmission is possible but considered less common [3]. Coinfection with immunosuppressive pathogens such as feline immunodeficiency virus (FIV) or feline leukemia virus (FeLV) predisposes cats to reactivation of latent toxoplasmosis and more severe clinical disease [9, 26, 29, 30]. Concurrent infection with feline coronavirus may also complicate the clinical picture, as chronic coronavirus infection can be exacerbated by toxoplasmosis [10]. Oocyst shedding is most intense during primary infection and typically lasts for 1 to 3 weeks, after which immunity usually prevents further shedding unless the cat is immunosuppressed [1, 6]. In a study of domiciled cats in the midwestern United States, T. gondii oocysts were not detected in feces, but seroprevalence increased with age, reaching 37.5% in adult domiciled cats and 57.9% in adult stray cats [11]. The high seroprevalence in stray populations suggests that environmental exposure is widespread and that management practices such as confinement and prevention of hunting reduce infection risk [4, 8].

Clinical Signs

General Clinical Manifestations

Most feline toxoplasmosis cases are subclinical, with seropositive cats showing no overt disease [12, 35]. However, when clinical signs occur, they can affect multiple organ systems. Acute toxoplasmosis may present with fever, anorexia, lethargy, and weight loss [13, 14]. Respiratory signs such as tachypnea, dyspnea, and coughing are common due to pneumonia; a study of 15 clinical cases reported respiratory involvement in a substantial proportion of animals [14, 26]. Hepatobiliary involvement can lead to icterus, elevated liver enzymes (aspartate aminotransferase, alanine aminotransferase), and hyperbilirubinemia [10, 26]. Gastrointestinal signs include vomiting and diarrhea, and in some cases, pancreatitis [12, 35]. Anemia, both regenerative and non-regenerative, is frequently observed, particularly in immunocompromised cats coinfected with retroviruses [10, 26]. The clinical course may be acute or chronic, and fatal disseminated toxoplasmosis has been documented, especially in cats receiving immunosuppressive therapy such as oclacitinib for allergic skin disease [9].

Ocular Toxoplasmosis

Ocular disease is a well recognized manifestation of feline toxoplasmosis, often occurring as a result of reactivation of tissue cysts in the eye [15, 35]. In a clinical series of 105 cats with ocular signs, 60 (57.14%) were seropositive for T. gondii [15]. Anterior uveitis was the most common finding, present in 38 cats (63.33%), followed by posterior segment involvement (20%), anterior chamber abnormalities (8.33%), corneal abnormalities (5%), and concurrent anterior uveitis with corneal involvement (3.34%) [15]. Bilateral ocular disease occurred in 25% of seropositive cats, while right-sided disease was slightly more frequent (41.67%) than left-sided (33.33%) [15]. Seropositive cats had significantly higher IgM and IgG index values compared to seronegative cats [15]. Ocular toxoplasmosis may be the sole clinical sign in otherwise healthy cats, and it is important to include toxoplasmosis in the differential diagnosis for any cat presenting with unexplained uveitis [15, 35].

Neurological Manifestations and Cat Toxoplasmosis Brain

Neurological signs are among the most serious consequences of feline toxoplasmosis and reflect the parasite's tropism for central nervous system (CNS) tissue [3, 16, 30]. The term "cat toxoplasmosis brain" encompasses the neuropathological changes induced by T. gondii, including meningoencephalitis, cerebral necrosis, and granuloma formation [16, 30]. Clinical neurological signs vary depending on the location and extent of CNS lesions and may include ataxia, seizures, circling, head pressing, behavioral changes, paresis, and cranial nerve deficits [13, 14, 30]. In a case series of 15 clinical feline toxoplasmosis cases, neurological abnormalities were documented in several animals, often concurrent with respiratory or ocular signs [14]. Fatal cerebral toxoplasmosis has been described in a cat coinfected with FeLV and feline infectious peritonitis virus, where histopathology revealed extensive protozoal cysts and necrotizing inflammation in the brain [30]. Immunocompromised cats, particularly those with retroviral infections, are at elevated risk for CNS toxoplasmosis [9, 26, 30]. The presence of bradyzoite cysts in brain tissue may persist for years without causing clinical signs, but any disruption of cell-mediated immunity can trigger reactivation and acute encephalitis [6, 5]. The behavioral term "toxoplasmosis cat lady disease" is a misnomer; there is no evidence that T. gondii infection in cats causes behavioral changes analogous to the reported alterations in rodents or humans. Feline toxoplasmosis does not produce a specific "cat lady disease" syndrome, and such phrasing should be avoided in scientific discourse. The only verified neurological sequelae are those directly attributable to inflammatory and necrotic lesions within the CNS.

Diagnosis

Diagnosis of feline toxoplasmosis requires an integrated approach combining serological, molecular, and sometimes histopathological methods [1, 24]. Given the high seroprevalence in many cat populations, a positive serological test does not confirm active disease; rather, it indicates exposure [24]. Clinical disease is more reliably diagnosed by demonstrating a rising IgG titer, the presence of IgM antibodies (suggesting recent infection or reactivation), or by detecting the organism or its DNA in tissues or body fluids [1, 24]. The diagnostic workflow is summarized in the Mermaid diagram below.

flowchart TD
    A[Suspected feline toxoplasmosis], > B{Serology: IgM and IgG}
    B, >|IgM positive, high or rising IgG| C[Likely active or recent infection]
    B, >|IgG positive only| D[Past exposure; assess clinical signs]
    B, >|Negative| E[Toxoplasmosis unlikely]
    C, > F{Confirm with PCR or histology}
    D, > G{Clinical signs consistent?}
    G, >|Yes| H[Consider PCR on blood, CSF, or BAL]
    G, >|No| I[Monitor; no treatment needed]
    F, > J[Positive PCR or cyst detection: confirm active disease]
    F, > K[Negative PCR: reassess other causes]
    H, > J
    H, > K

Serological Assays

Serological testing is the most common diagnostic method. The reference standard for many years has been the Sabin-Feldman dye test, but this is rarely used in practice because it requires live tachyzoites [11]. Modern veterinary laboratories primarily employ enzyme-linked immunosorbent assays (ELISAs) and immunochromatographic rapid tests [1, 17]. Commercial ELISA kits that detect IgG and IgM antibodies are widely available and offer good sensitivity and specificity [1, 18]. The choice of antigen is critical for diagnostic accuracy in cats. T. gondii lysate antigen (TLA) has demonstrated high concordance (94.27%) with the latex agglutination test (LAT) in IgG ELISA, outperforming individual recombinant antigens such as SAG2, GRA2, GRA6, GRA7, GRA15, and MIC10 [18]. However, a combination of recombinant SAG2 and select dense granule proteins (GRAs) achieved performance comparable to TLA (Kappa = 0.81) [18]. More recently, research has identified MIC17A, a micronemal protein highly expressed in merozoites but not in tachyzoites or bradyzoites, as a superior diagnostic marker for feline toxoplasmosis [2, 7]. When used as an antigen in ELISA, MIC17A reacted strongly with IgG antibodies from infected cats, while tachyzoite-stage antigens such as GRA1 and MIC3 reacted poorly [2]. This stage-specificity allows detection of entero-epithelial infection, which is directly relevant to oocyst shedding and transmission risk [2, 7, 18]. Immunochromatographic rapid tests, which detect both IgG and IgM, are convenient for point-of-care use and have been employed in seroprevalence surveys [17, 4]. In a study of 120 cats in Kuwait, 60% were IgG positive and 31.7% were IgM positive using an immunochromatographic assay [17]. Rapid tests are less sensitive than laboratory-based ELISAs and may yield false negatives in early infection [1].

Molecular Diagnostics

Polymerase chain reaction (PCR) targeting T. gondii DNA is highly sensitive and specific for detecting the parasite in blood, cerebrospinal fluid (CSF), bronchoalveolar lavage (BAL) fluid, aqueous humor, and tissue biopsies [1, 24]. PCR is especially valuable for confirming active disease in seropositive cats with compatible clinical signs [24]. Quantitative PCR (qPCR) can provide information on parasitic load. The sensitivity of PCR varies by sample type; blood PCR is less sensitive than tissue or CSF PCR, particularly in cats with chronic latent infection [1]. Newer molecular technologies, including loop-mediated isothermal amplification (LAMP) and nanomaterial-enhanced assays, are under development and may offer improved sensitivity and field applicability [1].

Advanced and Emerging Techniques

Recent reviews highlight the potential of artificial intelligence and machine learning algorithms to improve diagnostic precision by integrating serological, molecular, and imaging data [1]. Nanomaterial-based biosensors, such as those using gold nanoparticles or quantum dots, could enable rapid, low-cost detection of T. gondii antigens or nucleic acids at the point of care [1]. Another innovative approach is the carbon immunoassay, a simple serodiagnostic test that uses carbon particles to visualize antigen-antibody reactions; this method was developed in the 1980s but has been largely superseded by modern ELISAs [28]. A key priority in diagnostic development is the identification of antigens expressed specifically during the schizogony, bradyzoite, and sporulated oocyst stages, as these are most relevant to early detection and transmission interruption [1, 2].

Treatment

Treatment of clinical feline toxoplasmosis is indicated when active disease is confirmed or strongly suspected based on compatible clinical signs, serology (positive IgM or rising IgG), and exclusion of other etiologies [12, 14, 31]. The mainstay of therapy is clindamycin, administered orally or parenterally at a dosage of 10 to 20 mg/kg every 12 hours for 2 to 4 weeks [12, 15, 35]. Alternative antibiotics include trimethoprim-sulfonamide combinations, azithromycin, and pyrimethamine combined with a sulfonamide, although the latter may cause bone marrow suppression and is not routinely used in cats [12]. In a clinical trial of 60 cats with ocular toxoplasmosis treated with clindamycin and topical therapy (corticosteroids for uveitis), 46.7% showed complete response, 41.7% showed partial response, and 11.6% showed poor response [15]. Immunocompetent cats generally respond well to a 4-week course of clindamycin, whereas immunocompromised cats (e.g., those with FIV or FeLV) may have a poor prognosis despite therapy [9, 26]. In a study of 10 Siamese cats with clinical toxoplasmosis, the 3 immunocompetent cats gained weight and normalized their hemograms after treatment, while the 7 retrovirus-coinfected cats did not improve and were euthanized [26]. Adjunctive therapy may include supportive care: intravenous fluids, appetite stimulants, and treatment for secondary infections [12]. In cats with concurrent feline coronavirus infection, a 2- to 4-month course of the immunomodulator polyprenyl phosphate (Phosprenyl) has been reported to resolve anemia and liver enzyme elevations associated with toxoplasmosis [10]. However, the efficacy of immunomodulators is not established in controlled studies. Corticosteroids are contraindicated in active toxoplasmosis because they suppress cell-mediated immunity and can exacerbate the infection [12, 6]. In experimentally infected cats, administration of corticosteroids led to reactivation of latent disease and resumption of oocyst shedding [6]. Treatment should be continued for at least 2 weeks after clinical resolution, and serological monitoring may be used to confirm declining IgM or stable IgG titers [12, 14].

Zoonotic Considerations

Cats are the primary source of environmental contamination with T. gondii oocysts, which are highly resistant and can remain infectious in soil and water for months to years [1, 3]. Humans and other warm-blooded animals become infected through ingestion of sporulated oocysts from contaminated hands, food, or water, or through consumption of undercooked meat containing tissue cysts [3, 25]. The zoonotic risk from a single cat is highest during the first few weeks after primary infection when oocysts are shed in feces [1, 3]. In most cats, oocyst shedding occurs only once in a lifetime unless they become immunosuppressed [6]. The "toxoplasmosis cat lady disease" stereotype, which incorrectly links cat ownership with psychiatric disorders, has been perpetuated in popular culture but lacks scientific support. No credible evidence has been published demonstrating that owning cats or acquiring T. gondii from cats causes a distinct "cat lady disease" in humans. The zoonotic concern is valid, however, for pregnant women and immunocompromised individuals, as primary infection during pregnancy can lead to congenital toxoplasmosis, and reactivation in immunocompromised patients can cause severe encephalitis or disseminated disease [1, 3]. Veterinary professionals should counsel cat owners on hygiene measures: daily removal of feces from litter boxes (before oocysts sporulate), wearing gloves, hand washing, and keeping cats indoors to prevent hunting and subsequent oocyst shedding [1, 3]. Pregnant owners should avoid cleaning litter boxes altogether if possible [3]. Seroprevalence studies indicate that the risk of oocyst shedding is low in healthy, indoor-only cats, but any cat that hunts outdoors is at risk [4, 8, 11]. In Kuwait, a seroprevalence of 60% IgG and 31.7% IgM highlights the widespread exposure in some populations [17]. Education and routine surveillance are essential components of a One Health approach to toxoplasmosis prevention [1, 17, 4].

Prevention and Control

Preventing feline toxoplasmosis reduces both animal disease and zoonotic transmission. The most effective strategy is to prevent cats from hunting, feed only cooked or commercially processed food, and avoid raw meat diets [4, 3, 8]. Stray cat populations should be managed through spay/neuter programs and adoption to reduce environmental contamination [3]. Litter boxes should be cleaned daily, and litter can be disposed of in sealed bags [1]. Immunosuppressed cats (e.g., those on corticosteroids, oclacitinib, or with retroviral infections) should be monitored closely for signs of toxoplasmosis [9, 6]. In multi-cat households, new introductions should be screened serologically to prevent introduction of shedders [3]. Vaccination against T. gondii in cats is not currently available in most countries [12]. Development of diagnostic tests that can identify cats actively shedding oocysts is a research priority, and the use of merozoite-specific antigens such as MIC17A may enable such distinction [2, 7, 18]. At the population level, ongoing serosurveillance is necessary to track changes in prevalence and identify emerging risk factors [17, 4, 19, 20, 32, 34].

References

[1] Dan Zhao, Yanzhen Liao, Hao Liu et al. Comprehensive diagnostic approaches to feline toxoplasmosis: Bridging traditional methods and emerging technologies. Virulence. 2025. https://www.semanticscholar.org/paper/2e757aa2ddd10827f80fab2653e009ad1d5e71da

[2] Jinling Chen, Lilan Xue, Hongxia Hu et al. MIC17A is a novel diagnostic marker for feline toxoplasmosis. Animal Diseases. 2022. https://www.semanticscholar.org/paper/409a1c77abdc8102e0ee7ad5b4a222f8efdd3e71

[3] K. Bresciani, A. L. Galvão, A. L. D. Vasconcellos et al. EPIDEMIOLOGICAL ASPECTS OF FELINE TOXOPLASMOSIS. 2016. https://www.semanticscholar.org/paper/6b9f21d91d91295b742aef77632d2525479580ce

[4] G. Sioutas, I. Symeonidou, A. Gelasakis et al. Feline Toxoplasmosis in Greece: A Countrywide Seroprevalence Study and Associated Risk Factors. Pathogens. 2022. https://www.semanticscholar.org/paper/7a38aa6feab78b556c75fca605f426eadd8440c5

[5] J. P. Dubey, J. K. Frenkel. Feline toxoplasmosis from acutely infected mice and the development of Toxoplasma cysts. The Journal of Protozoology. 1976. https://www.semanticscholar.org/paper/8baf73ffc19ee8034b04927ed5eb249b3daa9e18

[6] J. Dubey, J. K. Frenkel. Immunity to Feline Toxoplasmosis: Modification by Administration of Corticosteroids. Veterinary Pathology-Supplement. 1974. https://www.semanticscholar.org/paper/7d02cb1226cf6abea11de16a6dd851250bc20241

[7] Özlem Günay-Esiyok, Ecem Su Koçkaya, Rana Yılmaz et al. The Potential of MIC17A both as an Entero-epithelial and Chronic Stage Marker for Detection of Feline Toxoplasmosis. Current Microbiology. 2026. https://www.semanticscholar.org/paper/170f603aa98f7dd6b215d4a83f5f76f844c9e861

[8] A. Brennan. Risk factors in feline toxoplasmosis. 2018. https://www.semanticscholar.org/paper/f488897999e2e89707722c6d17b4288f318c47a5

[9] A. Moore, A. Burrows, R. Malik et al. Fatal disseminated toxoplasmosis in a feline immunodeficiency virus-positive cat receiving oclacitinib for feline atopic skin syndrome. Veterinary Dermatology. 2022. https://www.semanticscholar.org/paper/c931267329077e9f22210c3439872dddff053542

[10] S. Savoyskaya, A. Sanin, I. Ogorodnikova et al. Phosprenyl usage as part of the complex therapy of feline chronic coronavirus infection complicated by toxoplasmosis. Russian Veterinary Journal. 2022. https://www.semanticscholar.org/paper/d2205256d3e3592683ec54c4e85a619eac09add0

[11] J. Dubey. Feline toxoplasmosis and coccidiosis: a survey of domiciled and stray cats. Journal of the American Veterinary Medical Association. 1973. https://www.semanticscholar.org/paper/ccb8d11ca9bbfc79aec59433b8a97df0159136cd

[12] S. Caney. Update on feline toxoplasmosis. 2021. https://www.semanticscholar.org/paper/04388a62c4aa2e740b6e424bd443e7a1366da8e9

[13] M. Lappin, C. Greene, S. Winston et al. Clinical Feline Toxoplasmosis. 1989. https://www.semanticscholar.org/paper/1ae2d5c4420cf0ff662e99d9964dc6c34a70036b

[14] M. Lappin, C. Greene, S. Winston et al. Clinical feline toxoplasmosis. Serologic diagnosis and therapeutic management of 15 cases. Journal of Veterinary Internal Medicine. 1989. https://www.semanticscholar.org/paper/188e9c3e7b48fcd3dd733c4dadbdd3bf4a2c1dbf

[15] K. M. Ali, A. M. Abu-Seida, M. Abuowarda. Feline ocular toxoplasmosis: seroprevalence, diagnosis and treatment outcome of 60 clinical cases. Polish Journal of Veterinary Sciences. 2021. https://www.semanticscholar.org/paper/0d19fc80bf1bde129d6b11a3e14b5e0b7dc7192c

[16] R. Hirth, S. W. Nielsen. Pathology

[17] S. M. Ibrahim, I. Mohamed, S. E. Suliman et al. Seroprevalence of Feline Toxoplasmosis in Kuwait State. International Journal of Current Microbiology and Applied Sciences. 2025. https://www.semanticscholar.org/paper/f05f6b05b012c996ed244740c03869e7c95c3f5b

[18] A. Abdelbaset, Hend Alhasan, Doaa Salman et al. Evaluation of recombinant antigens in combination and single formula for diagnosis of feline toxoplasmosis. Experimental Parasitology. 2017. https://www.semanticscholar.org/paper/1fd2239858e29ce336d8d273dd32e3c1ed51f467

[19] J. Teixeira, Jéssica S Oliveira, D. Almeida et al. Seroprevalence of feline toxoplasmosis in Teresina, Piauí, Brazil. 2016. https://www.semanticscholar.org/paper/b5a75e8076e477c63e0ad3cf290165adcea31440

[20] P. Jokelainen, O. Simola, E. Rantanen et al. Feline toxoplasmosis in Finland. Journal of Veterinary Diagnostic Investigation. 2012. https://www.semanticscholar.org/paper/6a4fbacb25ee047707fcc3cc04c3c600dc321216

[21] J. L. Faria, C. Couto, Sheron L Wierzynski et al. Feline Toxoplasmosis: Tumor Necrosis Factor, Nitric Oxide, and Free Radicals in Seropositive Cats. Journal of Parasitology. 2018. https://www.semanticscholar.org/paper/6949c8c0034df3c74f48a543ed58094bbdee2c85

[22] M. Petrak, J. Carpenter. FELINE TOXOPLASMOSIS. Journal of the American Veterinary Medical Association. 1965. https://www.semanticscholar.org/paper/b716bfc934da864c863f7e5d8c3624e2dcc7c73e

[23] Y. Omata, H. Oikawa, M. Kanda et al. Experimental feline toxoplasmosis: humoral immune responses of cats inoculated orally with Toxoplasma gondii cysts and oocysts. Nihon Juigaku Zasshi. The Japanese Journal of Veterinary Science. 1990. https://www.semanticscholar.org/paper/b51652947e0dfa715c4d08df67cd76221708e926